COYA

Company Overview — What Does Coya Therapeutics, Inc. Do?

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas. Coya Therapeutics, Inc. (COYA) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Howard Berman and employs approximately 6 people. With a market capitalization of $96M, COYA is one of the notable companies in the Healthcare sector.

Coya Therapeutics, Inc. (COYA) Stock Rating — Reduce (April 2026)

As of April 2026, Coya Therapeutics, Inc. receives a Reduce rating with a composite score of 31.6/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.COYA ranks #3,711 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Coya Therapeutics, Inc. ranks #616 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

COYA Stock Price and 52-Week Range

Coya Therapeutics, Inc. (COYA) currently trades at $4.17. The stock lost $0.36 (7.9%) in the most recent trading session. The 52-week high for COYA is $7.75, which means the stock is currently trading -46.2% from its annual peak. The 52-week low is $3.94, putting the stock 5.8% above its annual trough. Recent trading volume was 157K shares, suggesting relatively thin trading activity.

Is COYA Overvalued or Undervalued? — Valuation Analysis

Coya Therapeutics, Inc. (COYA) carries a value factor score of 31/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 3.43x, versus the sector average of 2.75x. The price-to-sales ratio is 23.48x, compared to 1.66x for the average Healthcare stock.

At current multiples, Coya Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Coya Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Coya Therapeutics, Inc. (COYA) earns a quality factor score of 26/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -71.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -61.0% versus the sector average of -33.1%.

On a margin basis, Coya Therapeutics, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -2321.9% (sector: -66.1%). Net profit margin stands at -2206.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 4.1% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

COYA Debt, Balance Sheet, and Financial Health

Coya Therapeutics, Inc. has a debt-to-equity ratio of 17.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 8.73x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $28M.

COYA has a beta of 0.94, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Coya Therapeutics, Inc. is 45/100, reflecting average volatility within the normal range for its sector.

Coya Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Coya Therapeutics, Inc. reported revenue of $4M and earnings per share (EPS) of $-0.13. Net income for the quarter was $-20M. Gross margin was 100.0%. Operating income came in at $-21M.

In Q3 2025, Coya Therapeutics, Inc. reported revenue of $4M and earnings per share (EPS) of $-0.13. Net income for the quarter was $-2M. Operating income came in at $-2M.

In Q2 2025, Coya Therapeutics, Inc. reported revenue of $163,616 and earnings per share (EPS) of $-0.36. Net income for the quarter was $-6M. Revenue grew -95.2% year-over-year compared to Q2 2024. Operating income came in at $-6M.

In Q1 2025, Coya Therapeutics, Inc. reported revenue of $257,884 and earnings per share (EPS) of $-0.44. Net income for the quarter was $-7M. Revenue grew 103.3% year-over-year compared to Q1 2024. Operating income came in at $-8M.

Over the past 8 quarters, Coya Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $126,838 to $4M. Investors analyzing COYA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

COYA Dividend Yield and Income Analysis

Coya Therapeutics, Inc. (COYA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

COYA Momentum and Technical Analysis Profile

Coya Therapeutics, Inc. (COYA) has a momentum factor score of 21/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 32/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 62/100 reflects moderate short selling activity.

COYA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Coya Therapeutics, Inc. (COYA) ranks #616 out of 838 stocks based on the Blank Capital composite score. This places COYA in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing COYA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full COYA vs S&P 500 (SPY) comparison to assess how Coya Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

COYA Next Earnings Date

No upcoming earnings date has been announced for Coya Therapeutics, Inc. (COYA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy COYA? — Investment Thesis Summary

The quantitative profile for Coya Therapeutics, Inc. suggests caution. The quality score of 26/100 flags below-average profitability. The value score of 31/100 indicates premium valuation. Momentum is weak at 21/100, a headwind for near-term performance.

In summary, Coya Therapeutics, Inc. (COYA) earns a Reduce rating with a composite score of 31.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on COYA stock.

Related Resources for COYA Investors

Explore more research and tools: COYA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare COYA head-to-head with peers: COYA vs AZN, COYA vs SLGL, COYA vs VMD.